TX-WEA
12.7.2021 14:34:06 CEST | Business Wire | Press release
The Women’s Entrepreneurship Accelerator (WEA), a leading driver for increased women’s economic participation, joined the Generation Equality Forum in Paris (June 30-July 2) through the “Drivers of Change” Program. 26 years after the Beijing Declaration, the Generation Equality Forum, convened by UN Women and co-hosted by the governments of Mexico and France, is the “most critical moment in a generation to invest in gender equality and accelerate momentum for women’s safety, leadership and economic opportunity1 . 50,000 people virtually engaged in the Forum which gathered 1,000 commitment-makers, recorded $40 billion of investments for gender equality in support of a 5-year plan to act for equal across 7 areas of action.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210712005178/en/
On July 2, the Accelerator hosted a panel titled “Building a Transformative Strategy for Gender-Responsive Procurement,” aiming at creating awareness of the disproportionately complex and interconnected barriers on women’s entrepreneurship and promoting gender-responsive procurement strategies. Globally, 1 in 3 businesses are owned by women2 , yet women win only 1% of the procurement spend of governments and large corporations3 . Speakers shared insights and concrete advice substantiated by their own journey on how to implement inclusive procurement strategies.
Launched in 2019, the Women’s Entrepreneurship Accelerator is a multi-partner initiative designed to inspire, educate, and empower women entrepreneurs around the world. The mission of the Accelerator is to eliminate barriers for women entrepreneurs through four Pathways of Empowerment: Education, Funding, Advocacy, and Participation. With no qualifying barriers to participate, the global initiative, incepted by Mary Kay Inc., is a strategic collaboration developed in consultation with five United Nations agencies.
“We believe that gender-responsive procurement can make an enormous impact which accelerates the inclusion of women-owned businesses throughout the supply chain,” said Julia Simon, Chief Legal & Diversity Officer at Mary Kay Inc. “The Accelerator encourages the public and private sectors to make inclusive procurement a priority and drive the systemic change that women need. Supporting women entrepreneurs is critical for sustainable growth.”
Simon was one of the panelists featured during Gender Equality Forum’s Gender-Responsive Procurement discussion. She was joined by Elizabeth Vazquez, CEO and Co-Founder of WEConnect International and Jamila Belabidi, Purchases Director, Global Women Economic Empowerment & Global Innovation, Procter & Gamble. Sonia Dridi, journalist & Washington DC correspondent for France 24 and Europe 1, moderated the session.
“It’s a $93 trillion global economy, but women continue to be invisible as suppliers of products and services in our global value chains,” said Vazquez. “This massive market failure must be corrected with urgency so that more women can contribute to and benefit from inclusive economic prosperity and job creation in support of SDG5.”
“At P&G, our focus on gender equality is foundational and integrated into our business, as such, we are committed to spending $10 billion with women-owned and women-led businesses by 2025,” said Jamila Belabidi, Purchases Director, Global Women’s Economic Empowerment & Global Innovation at Procter & Gamble.
At the event, WEA also joined four of the Generation Equality Action Coalitions through policy, programmatic, and advocacy commitments: Economic Justice and Rights; Feminist Action for Climate Justice; Technology and Innovation for Gender Equality; and Feminist Movements and Leadership. The Accelerator also committed to empower 5 million women by the end of 2030 by alleviating the main economic and social roadblocks faced by women entrepreneurs.
The Accelerator’s participation in the Generation Equality Forum Action Coalitions is just the latest in a series of steps taken by the organization to raise awareness of women’s equality post COVID:
-
On March 16, 2021, Deborah Gibbins, Mary Kay’s Chief Operations Officer, joined the UN Global Compact Target Gender Equality
meeting on behalf of the Accelerator. Gibbins highlighted data freshly released by the World Bank revealing that on average across the world, women have three quarters of the legal rights of men. She challenged companies to take a stand against legal discriminations and advocate for reform to close the gaps so that women can achieve their full potential. The event brought together over 5,000 people from the business sector, the United Nations, member states, and civil society organizations from over 100 countries, with 75% of the participants representing the private sector.
- On March 24, 2021, on the sidelines of the Commission on the Status of Women (CSW65), the Women’s Empowerment Accelerator hosted a panel titled: “Women Leading Economic Recovery Through Entrepreneurship,” with five UN agency partners. The collective highlighted the need for public-private sector partnerships to help shape an enabling ecosystem for women entrepreneurs.
- On June 15-16, 2021, at the UN Global Compact Leaders Summit , Gibbins spoke at the “Women in Sustainability: Innovating in a Man’s World” main stage session advocating for women entrepreneurs as the role models needed by the economy and the society and emphasizing the critical mission of the Accelerator: “Women entrepreneurship will play a key role in the successful pandemic recovery. This is why the mission of the Women’s Entrepreneurship Accelerator is so timely. And, this is why women entrepreneurs need a framework of this magnitude,” said Gibbins. The annual Summit convened virtually more than 25,000 leaders from business, government, the UN, and civil society, to take stock of the state of progress and to drive collective action towards alleviating climate crisis, global pandemic, economic disparities, and social inequalities.
About the Women’s Entrepreneurship Accelerator
The Women’s Entrepreneurship Accelerator is a multi-partner initiative designed to inspire, educate, and empower women entrepreneurs around the world. The mission of the Accelerator is to eliminate barriers for women entrepreneurs around the world through Four Pathways of Empowerment: Education, Funding, Advocacy, and Participation. With no qualifying barriers to participate, the global initiative incepted by Mary Kay Inc. is a strategic collaboration developed in consultation with five United Nations agencies: UN Women, International Labour Organization (ILO), International Trade Centre (ITC), UN Global Compact (UNGC), and the United Nations Development Programme (UNDP). The Accelerator aims to economically empower 5 million women by the end of 2030. Learn more at https://www.we-accelerate.com/
1
https://forum.generationequality.org/home
2
World Bank (2020). Enterprise Surveys, World Bank Gender Data Portal
cited by World Bank Blogs (2020) Women entrepreneurs needed – stat!
3
Vazquez and Sherman (2014). Cited by UN Women (2017) The Power of Procurement: How to source from women-owned businesses
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210712005178/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
